Biologics ‘don’t increase cancer risk’ in IBD patients

A small study suggests there's no need to avoid immunosuppressive therapy even for those with prior malignancy
Microscope photo of a large intestine section with inflammation

Prior history of cancer in patients with inflammatory bowel disease should not preclude the prescription of biologic therapy, according to results from a retrospective study.

US researchers made the call after finding no association between the use of ustekinumab, vedolizumab and TNF inhibitors with the risk of new or recurrent cancer in this clinical setting.